BioCryst (BCRX) Discontinues Development of Avoralstat for Diabetic Macular Edema, Focusing on Rare Diseases
Historical Background of Avoralstat Development Discontinuation
Avoralstat (BCX4161), developed by BioCryst Pharmaceuticals (BCRX), is an inhibitor targeting plasma kallikrein. Originally developed as an oral drug for hereditary angioedema (HAE) and advanced to Phase 3 (OPuS-2), it failed to demonstrate a significant reduction in the frequency of acute attacks compared to placebo, failing to meet its primary endpoint. Subsequently, the company attempted to repurpose avoralstat as a treatment for diabetic macular edema (DME), a market estimated at $4 to $5.8 billion, by changing the delivery method to suprachoroidal injection and initiating a Phase 1b trial (BCX4161-111). However, given the intense competition in the ophthalmology field, unlike the rare disease market, the company determined that it would be difficult to overcome the high initial development costs and clinical uncertainties, leading to the complete discontinuation of this second attempt at repurposing.
Streamlining Through Strategic Portfolio Management
This decision stems from BioCryst's careful consideration of opportunity costs, focusing its limited resources on the commercially proven rare disease area. The DME clinical trial requires direct injection into the eye, which poses challenges in patient compliance and requires a complex clinical infrastructure, making it a high-cost endeavor. In contrast, BioCryst has already demonstrated its ability to generate substantial cash flow with the success of Orladeyo (berotralstat), an HAE treatment that received FDA approval in December 2020. Therefore, by proactively terminating the early-stage Phase 1b avoralstat program, the company aims to maximize capital efficiency by focusing its research and development (R&D) efforts on the global expansion of Orladeyo and the development of its follow-up rare disease pipeline.
Fierce Competition in the Ophthalmic Drug Market
The DME market is dominated by Regeneron's Eylea (aflibercept) and Roche's Vabysmo (faricimab). Recently, the rapid market penetration of Vabysmo, which extends the dosing interval to up to 16 weeks, the launch of high-dose Eylea HD, and the entry of biosimilars such as Opuviz have intensified price pressure. Even if the novel mechanism of action of avoralstat were to successfully complete the Phase 1b trial, it would have been realistically difficult to demonstrate overwhelming superiority over the existing standard of care (SOC) in this market through a large-scale Phase 3 trial and secure commercial competitiveness.
Transformation into a Rare Disease-Focused Biotech
Consequently, the complete discontinuation of avoralstat signals BioCryst's intention to abandon the general chronic disease area and fully transform into a high-value rare disease-focused company. The reduction in avoralstat R&D costs will improve short-term financial stability, and market attention will now focus on the company's follow-up rare disease pipeline, including Factor D inhibitors. Although there may be some disappointment in the short term due to the failure to diversify the pipeline, this decision is being viewed as a typical example of a small biotech company adhering to the formula for survival and growth by preventing resource dispersion and focusing on its strengths.
BioCryst's decision to discontinue the development of avoralstat is a strategic move to focus resources on its existing rare disease portfolio, such as Orladeyo, which generates hundreds of millions of dollars in annual revenue, rather than pursuing the $4 to $5.8 billion DME market. By proactively cutting R&D spending in the early Phase 1b stage, the company expects to alleviate short-term financial burdens. However, in the medium to long term, the commercial value of avoralstat, which has lost competitiveness in the ophthalmology market dominated by strong standard-of-care treatments such as Eylea and Vabysmo, has been lost, resulting in the loss of an opportunity to diversify its growth drivers. For researchers and industry professionals, this case serves as an example of the limitations of applying suprachoroidal injection technology and the kallikrein inhibition mechanism in the ophthalmology field.